Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (July 2022)
23 slides from Adalta's investor presentation, Jul 25, 2022
Slide 1: Developing high value drugs for challenging diseases
For personal use only Developing high value drugs for challenging diseases Tim Oldham PhD, CEO and Managing Director July 2022
Slide 2: Disclaimer
COMPANY OVERVIEW – JULY 2022 2 Disclaimer For personal use only Investment in AdAlta is subject to This presentation may contain forward- There is no guarantee that the investment risk, including possible loss looking statements regarding the Company’s research and development of income and capital
Slide 3: AdAlta at a glance
COMPANY OVERVIEW – JULY 2022 3 AdAlta at a glance For personal use only Building out pipeline Targeting 10 programs by end 2023 Immuno-oncology: two co-development collaborations 1. i-CAR-T with Carina Biotech: US$20b market by 2028 2. GZMB i-PET imaging agent with GE Healthcare: US$6.4b market Fibr
Slide 4: Four human health needs AdAlta is addressing today
COMPANY OVERVIEW – JULY 2022 4 Four human health needs AdAlta is addressing today For personal use only Antibodies cannot do everything! AdAlta’s i-bodies are a differentiated drug discovery platform for difficult diseases Idiopathic Pulmonary Fibrosis: degenerative, fatal AdAlta’s AD-214 could meet
Slide 5: Platform: i-bodies
For personal use only Platform: i-bodies
Slide 6: i-bodies: sdAB-like molecules with engineered binding loops
COMPANY OVERVIEW – JUNE 2022 6 i-bodies: sdAB-like molecules with engineered binding loops conferring unique binding properties For personal use only i-bodies are combination of i-body library contains 1010 1 a human protein with unique long loop 2 unique i-bodies. Each unique i-body has binding sit
Slide 7: i-bodies allow high affinity, high specificity binding to intractable targets
COMPANY OVERVIEW – JUNE 2022 7 i-bodies allow for high affinity, high specificity binding to targets that are intractable for traditional antibodies For personal use only Small Antibodies i-bodies Flexible, modular formats Molecules CAR cell therapy ADC/ radiotherapeutic Bi-specific Fc-fusion i-bodi
Slide 8: Lead program: AD-214
For personal use only Lead program: AD-214 8
Slide 9: About Idiopathic Pulmonary Fibrosis (IPF)
COMPANY OVERVIEW – JULY 2022 9 About | Idiopathic Pulmonary Fibrosis (IPF) For personal use only Scaring and stiffening of the lungs progressively and irreversibly reduces lung function >300,000 people living with IPF; 40,000 people die from IPF every year Only 3.8 years median survival after diagno
Slide 10: AD-214 | Completed Phase I, multiple indication options
COMPANY OVERVIEW – JULY 2022 10 AD-214 | Completed Phase I, multiple indication options For personal use only AD-214 is a first in class anti-fibrotic Multiple indication and partner potential • i-body-Fc fusion targeting CXCR4 • US$ billion need in many fibrosis indications • Pre-clinical efficacy
Slide 11: An inhaled formulation of AD-214 would be a superior option for IPF
COMPANY OVERVIEW – JULY 2022 11 An inhaled formulation of AD-214 would be a superior option for IPF For personal use only Improved bioavailability Greater patient convenience Enhanced cost effectiveness § AD-214 delivered direct to fibrotic areas § Self administration (no scheduled clinic § Lower dr
Slide 12: Inhaled AD-214 | Milestones and opportunities
COMPANY OVERVIEW – JULY 2022 12 Inhaled AD-214 | Milestones and opportunities For personal use only September 2022 quarter December 2022 quarter First half 2023 • Antifibrotic effects in cultured human lung tissue • Manufacturing AD-214 • Inhaled AD-214 for toxicology studies formulation selected •
Slide 13: AD-214 | Valuable IPF partnering options as early as Phase I
COMPANY OVERVIEW – JULY 2022 13 AD-214 | Valuable IPF partnering options as early as Phase I For personal use only Date Licensee Licensor Transaction Terms Clinical Phase Nov-21 US$254m Upfront 2 (Ready) Nov-21 €320m Milestones 2 (Ready) US$152m Upfront Sep-21 2 (Ready) +US$602m Milestones US$390m U
Slide 14: Co-developed immuno-oncology assets
For personal use only Co-developed immuno-oncology assets 14
Slide 15: About CAR-T therapies
COMPANY OVERVIEW – JULY 2022 15 About | CAR-T therapies For personal use only CAR-T therapies are providing new hope for patients with cancer who have failed all other options Therapy involves removing immune cells from blood and re-engineering them so they “see” cancer as a pathogen Already 6 FDA-a
Slide 16: i-bodies enable optimized CAR constructs (i-CARs)
COMPANY OVERVIEW – JUNE 2022 16 i-bodies enable optimized CAR constructs (i-CARs) For personal use only Feature Benefit Superior i-CAR products • Increased CAR gene cassette/vector capacity, • CARs against novel tumor antigens Small size efficient multi-functional CAR cell creation • Dual and bi-spe
Slide 17: i-CAR-T assets | Carina co-development collaboration
COMPANY OVERVIEW – JULY 2022 17 i-CAR-T assets | Carina co-development collaboration For personal use only AdAlta and Carina are combining i-bodies and a world class CAR-T platform to create iCAR-Ts that could offer improved precision, performance and persistence Further expands AdAlta’s pipeline in
Slide 18: About Immuno-oncology (I/O) PET imaging
COMPANY OVERVIEW – JULY 2022 18 About | Immuno-oncology (I/O) PET imaging For personal use only Immuno-oncology (I/O) drug market is worth US$95 billion1 … … but only 20-40% of patients respond2 to therapy Granzyme B (GZMB) is produced by immune cells to kill cancer: potential biomarker of I/O drug
Slide 19: GZMB i-PET imaging asset | GE Healthcare co-development collaboration
COMPANY OVERVIEW – JULY 2022 19 GZMB i-PET imaging asset | GE Healthcare co-development collaboration For personal use only AdAlta and GE are co-developing a GZMB i-body PET imaging (iPET) asset to evaluate the effectiveness of immuno-oncology drugs Revenue generative pipeline asset • AdAlta earns r
Slide 20: I/O assets | Milestones and opportunities
COMPANY OVERVIEW – JULY 2022 20 I/O assets | Milestones and opportunities For personal use only September 2022 December 2022 First half 2023 TBD quarter quarter • Initial in vitro • Updates cancer cell killing • A-i-CAR-T in • Full in vitro provided in screening assays cancer cell killing vivo proof
Slide 21: Corporate snapshot
COMPANY OVERVIEW – JULY 2022 21 Corporate snapshot For personal use only Key financial details (21 July 2022) Share price performance (last 12 months) 0.12 4.0 ASX code 1AD 3.5 Market capitalisation A$15.08m 0.10 Share price (12 month closing range) A$0.048 ($0.045 - 0.114) 3.0 0.08 Share price (A$)
Slide 22: Investment proposition
COMPANY OVERVIEW – JULY 2022 22 Investment proposition For personal use only Fibrosis/inflammation Immuno-oncology Lead asset advancing to Phase II 2 x co-development collaborations to i-body platform to create value >$3b market potential in first indication1 leverage platform ü Carina Biotech: $20b
Slide 23: Contact
For personal use only Contact: Tim Oldham, CEO and Managing Director [email protected] www.adalta.com.au